Changing Neoadjuvant and Adjuvant Paradigms in HER2-Positive Breast Cancer: What Surgeons Need to Know

ESSO, Medscape
10/16/20, 3:30 PM
Europe/Paris GMT+2

Description

PROGRAM Friday, 16 October 2020

12:30

Introduction

Tibor Kovacs, PhD, FRCS, FEBS, Med. Habil.

12:34

The Changing Paradigm in Neoadjuvant/Adjuvant: What Is the Evidence?

Christian Jackisch, MD, PhD

12:46

Neoadjuvant or Not? What Is the Best Practice?

Fabien Reyal, MD, PhD

12:58

Assessment of Pathologic Complete Response and Residual Disease: What Is the State of the Art?

Michael Knauer, MD, PhD, FEBS

13:10

Putting It Together in Practice: What Does It All Mean for Surgeons?

Tibor Kovacs, PhD, FRCS, FEBS, Med. Habil. and Faculty Panel

13:28

So, What Do Surgeons Need to Know?

Tibor Kovacs, PhD, FRCS, FEBS, Med. Habil.

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Tibor Kovacs

Introduction, The Changing Paradigm in Neoadjuvant/Adjuvant: What Is the Evidence?, Neoadjuvant or Not? What Is the Best Practice?, Assessment of Pathologic Complete Response and Residual Disease: What Is the State of the Art?, Putting It Together in Practice: What Does It All Mean for Surgeons? So, What Do Surgeons Need to Know?

Inglês

 

Speakers

Christian Jackisch, Michael Knauer, Fabien Reyal

 

Link to the Event

Banner to the Event

Changing Neoadjuvant and Adjuvant Paradigms in HER2-Positive Breast Cancer: What Surgeons Need to Know